Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04954287 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents
A Phase 1 study, sponsored by CyanVac.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT04954287 is a Phase 1 study that has completed, run by CyanVac. The registered enrollment target is 72 participants.
The verdict
NCT04954287, a Phase 1 study, has completed, sponsored by CyanVac.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This Phase 1 trial is an open-label trial to evaluate the safety, reactogenicity and immunogenicity of two dosages (10\^6 PFU and 10\^7 PFU) of intranasal CVXGA1 administered as a single dose in healthy adults age 18-55 years and in adolescents age 12-17.
Interventions
- BIOLOGICAL CVXGA1 low dose
- BIOLOGICAL CVXGA1 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2023-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04954287
The ClinicalTrials.gov registry entry for NCT04954287 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CyanVac, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CVXGA1 low dose is the first listed.
NCT04954287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04954287 about?
NCT04954287 is a clinical study titled "Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents". This Phase 1 trial is an open-label trial to evaluate the safety, reactogenicity and immunogenicity of two dosages (10\^6 PFU and 10\^7 PFU) of intranasal CVXGA1 administered as a single dose in healthy adults age 18-55 years and in adolescents age 12-17.
What is the current status of trial NCT04954287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-08-06. Estimated completion is 2023-06-10.
What interventions are being tested in trial NCT04954287?
The interventions under investigation include: CVXGA1 low dose (BIOLOGICAL), CVXGA1 high dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT04954287?
This trial is sponsored by CyanVac, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.